Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines

Authors: Ansgar M Chromik, Adrien Daigeler, Daniel Bulut, Annegret Flier, Christina May, Kamran Harati, Jan Roschinsky, Dominique Sülberg, Peter R Ritter, Ulrich Mittelkötter, Stephan A Hahn, Waldemar Uhl

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

Taurolidine (TRD) represents an anti-infective substance with anti-neoplastic activity in many malignant cell lines. So far, the knowledge about the cell death inducing mechanisms and pathways activated by TRD is limited. The aim of this study was therefore, to perform a comparative analysis of cell death induction by TRD simultaneously in different malignant cell lines.

Materials and methods

Five different malignant cell lines (HT29/Colon, Chang Liver/Liver, HT1080/fibrosarcoma, AsPC-1/pancreas and BxPC-3/pancreas) were incubated with increasing concentrations of TRD (100 μM, 250 μM and 1000 μM) for 6 h and 24 h. Cell viability, apoptosis and necrosis were analyzed by FACS analysis (Propidiumiodide/AnnexinV staining). Additionally, cells were co-incubated with the caspase Inhibitor z-VAD, the radical scavenger N-Acetylcystein (NAC) and the Gluthation depleting agent BSO to examine the contribution of caspase activation and reactive oxygen species in TRD induced cell death.

Results

All cell lines were susceptible to TRD induced cell death without resistance toward this anti-neoplastic agent. However, the dose response effects were varying largely between different cell lines. The effect of NAC and BSO co-treatment were highly different among cell lines - suggesting a cell line specific involvement of ROS in TRD induced cell death. Furthermore, impact of z-VAD mediated inhibition of caspases was differing strongly among the cell lines.

Conclusion

This is the first study providing a simultaneous evaluation of the anti-neoplastic action of TRD across several malignant cell lines. The involvement of ROS and caspase activation was highly variable among the five cell lines, although all were susceptible to TRD induced cell death. Our results indicate, that TRD is likely to provide multifaceted cell death mechanisms leading to a cell line specific diversity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg. 1994, 81: 1054-1056. 10.1002/bjs.1800810743.CrossRef Baker DM, Jones JA, Nguyen-Van-Tam JS, Lloyd JH, Morris DL, Bourke JB, Steele RJ, Hardcastle JD: Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery. Br J Surg. 1994, 81: 1054-1056. 10.1002/bjs.1800810743.CrossRef
2.
go back to reference Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008, 8: 102-10.1186/1471-2334-8-102.CrossRef Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infect Dis. 2008, 8: 102-10.1186/1471-2334-8-102.CrossRef
3.
go back to reference Koldehoff M, Zakrzewski JL: Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2004, 24: 491-495. 10.1016/j.ijantimicag.2004.06.006.CrossRef Koldehoff M, Zakrzewski JL: Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. Int J Antimicrob Agents. 2004, 24: 491-495. 10.1016/j.ijantimicag.2004.06.006.CrossRef
4.
go back to reference Jacobi CA, Menenakos C, Braumann C: Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 2005, 16: 917-921. 10.1097/01.cad.0000176502.40810.b0.CrossRef Jacobi CA, Menenakos C, Braumann C: Taurolidine--a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs. 2005, 16: 917-921. 10.1097/01.cad.0000176502.40810.b0.CrossRef
5.
go back to reference Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA: Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis. 2005, 22: 77-83. 10.1007/s10585-005-4695-4.CrossRef Braumann C, Schoenbeck M, Menenakos C, Kilian M, Jacobi CA: Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats. Clin Exp Metastasis. 2005, 22: 77-83. 10.1007/s10585-005-4695-4.CrossRef
6.
go back to reference Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkotter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg. 2007, 20: 339-348. 10.1080/08941930701772157.CrossRef Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkotter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg. 2007, 20: 339-348. 10.1080/08941930701772157.CrossRef
7.
go back to reference Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 2008, 32: 1205-1220. 10.3892/ijo_32_6_1205.CrossRef Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkötter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 2008, 32: 1205-1220. 10.3892/ijo_32_6_1205.CrossRef
8.
go back to reference Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res. 2002, 22: 809-814. Stendel R, Stoltenburg-Didinger G, Al Keikh CL, Wattrodt M, Brock M: The effect of taurolidine on brain tumor cells. Anticancer Res. 2002, 22: 809-814.
9.
go back to reference Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy. 2009, 5: 194-210. 10.4161/auto.5.2.7404.CrossRef Stendel R, Biefer HR, Dekany GM, Kubota H, Munz C, Wang S, Mohler H, Yonekawa Y, Frei K: The antibacterial substance taurolidine exhibits anti-neoplastic action based on a mixed type of programmed cell death. Autophagy. 2009, 5: 194-210. 10.4161/auto.5.2.7404.CrossRef
10.
go back to reference Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. J Surg Res. 2007, 143: 372-378. 10.1016/j.jss.2007.01.041.CrossRef Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. J Surg Res. 2007, 143: 372-378. 10.1016/j.jss.2007.01.041.CrossRef
11.
go back to reference Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol. 2007, 96: 241-248. 10.1002/jso.20827.CrossRef Sun BS, Wang JH, Liu LL, Gong SL, Redmond HP: Taurolidine induces apoptosis of murine melanoma cells in vitro and in vivo by modulation of the Bcl-2 family proteins. J Surg Oncol. 2007, 96: 241-248. 10.1002/jso.20827.CrossRef
12.
go back to reference Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer. 2007, 56: 327-336. 10.1016/j.lungcan.2007.01.024.CrossRef Opitz I, Sigrist B, Hillinger S, Lardinois D, Stahel R, Weder W, Hopkins-Donaldson S: Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma. Lung Cancer. 2007, 56: 327-336. 10.1016/j.lungcan.2007.01.024.CrossRef
13.
go back to reference Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J. 2009, 34: 1399-1407. 10.1183/09031936.00102308.CrossRef Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J. 2009, 34: 1399-1407. 10.1183/09031936.00102308.CrossRef
14.
go back to reference Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 2008, 27: 82-10.1186/1756-9966-27-82.CrossRef Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 2008, 27: 82-10.1186/1756-9966-27-82.CrossRef
15.
go back to reference Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs. 2007, 25: 305-312. 10.1007/s10637-007-9052-9.CrossRef Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B: Taurolidine: a novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs. 2007, 25: 305-312. 10.1007/s10637-007-9052-9.CrossRef
16.
go back to reference Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol. 2006, 4: 34-10.1186/1477-7819-4-34.CrossRef Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA: Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case. World J Surg Oncol. 2006, 4: 34-10.1186/1477-7819-4-34.CrossRef
17.
go back to reference Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 2004, 24: 1143-1147. Stendel R, Picht T, Schilling A, Heidenreich J, Loddenkemper C, Janisch W, Brock M: Treatment of glioblastoma with intravenous taurolidine. First clinical experience. Anticancer Res. 2004, 24: 1143-1147.
18.
go back to reference Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H, Bigler L: Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet. 2007, 46: 513-524. 10.2165/00003088-200746060-00005.CrossRef Stendel R, Scheurer L, Schlatterer K, Stalder U, Pfirrmann RW, Fiss I, Mohler H, Bigler L: Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patients. Clin Pharmacokinet. 2007, 46: 513-524. 10.2165/00003088-200746060-00005.CrossRef
19.
go back to reference Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK: The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007, 47: 697-703. 10.1177/0091270007299929.CrossRef Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK: The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007, 47: 697-703. 10.1177/0091270007299929.CrossRef
20.
go back to reference Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. N Engl J Med. 2009, 361: 1570-1583. 10.1056/NEJMra0901217.CrossRef Hotchkiss RS, Strasser A, McDunn JE, Swanson PE: Cell death. N Engl J Med. 2009, 361: 1570-1583. 10.1056/NEJMra0901217.CrossRef
21.
go back to reference Hail N, Carter BZ, Konopleva M, Andreeff M: Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis. 2006, 11: 889-904. 10.1007/s10495-006-6712-8.CrossRef Hail N, Carter BZ, Konopleva M, Andreeff M: Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis. 2006, 11: 889-904. 10.1007/s10495-006-6712-8.CrossRef
22.
go back to reference Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 2004, 54: 249-258. 10.1007/s00280-004-0806-1.CrossRef Darnowski JW, Goulette FA, Cousens LP, Chatterjee D, Calabresi P: Mechanistic and antineoplastic evaluation of taurolidine in the DU145 model of human prostate cancer. Cancer Chemother Pharmacol. 2004, 54: 249-258. 10.1007/s00280-004-0806-1.CrossRef
23.
go back to reference Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res. 2002, 22: 1959-1964. Han Z, Ribbizi I, Pantazis P, Wyche J, Darnowski J, Calabresi P: The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism. Anticancer Res. 2002, 22: 1959-1964.
24.
go back to reference Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005, 102: 1055-1068. 10.3171/jns.2005.102.6.1055.CrossRef Rodak R, Kubota H, Ishihara H, Eugster HP, Konu D, Mohler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005, 102: 1055-1068. 10.3171/jns.2005.102.6.1055.CrossRef
25.
go back to reference Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 2003, 23: 2309-2314. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H: Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res. 2003, 23: 2309-2314.
26.
go back to reference Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkotter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 2008, 32 (6): 1205-20. 10.3892/ijo_32_6_1205.CrossRef Daigeler A, Chromik AM, Geisler A, Bulut D, Hilgert C, Krieg A, Klein-Hitpass L, Lehnhardt M, Uhl W, Mittelkotter U: Synergistic apoptotic effects of taurolidine and TRAIL on squamous carcinoma cells of the esophagus. Int J Oncol. 2008, 32 (6): 1205-20. 10.3892/ijo_32_6_1205.CrossRef
27.
go back to reference McCourt M, Wang JH, Sookhai S, Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 2000, 7: 685-691. 10.1007/s10434-000-0685-6.CrossRef McCourt M, Wang JH, Sookhai S, Redmond HP: Taurolidine inhibits tumor cell growth in vitro and in vivo. Ann Surg Oncol. 2000, 7: 685-691. 10.1007/s10434-000-0685-6.CrossRef
28.
go back to reference Nici L, Monfils B, Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res. 2004, 10: 7655-7661. 10.1158/1078-0432.CCR-0196-03.CrossRef Nici L, Monfils B, Calabresi P: The effects of taurolidine, a novel antineoplastic agent, on human malignant mesothelioma. Clin Cancer Res. 2004, 10: 7655-7661. 10.1158/1078-0432.CCR-0196-03.CrossRef
29.
go back to reference Opitz I, Veen Van der H, Witte N, Braumann C, Mueller JM, Jacobi CA: Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model. Eur Surg Res. 2007, 39: 129-135. 10.1159/000100109.CrossRef Opitz I, Veen Van der H, Witte N, Braumann C, Mueller JM, Jacobi CA: Instillation of taurolidine/heparin after laparotomy reduces intraperitoneal tumour growth in a colon cancer rat model. Eur Surg Res. 2007, 39: 129-135. 10.1159/000100109.CrossRef
30.
go back to reference Griffith OW, Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979, 254: 7558-7560. Griffith OW, Meister A: Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979, 254: 7558-7560.
31.
go back to reference Estrela JM, Ortega A, Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006, 43: 143-181. 10.1080/10408360500523878.CrossRef Estrela JM, Ortega A, Obrador E: Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006, 43: 143-181. 10.1080/10408360500523878.CrossRef
32.
go back to reference Braumann C, Henke W, Jacobi CA, Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer. 2004, 112: 225-230. 10.1002/ijc.20393.CrossRef Braumann C, Henke W, Jacobi CA, Dubiel W: The tumor-suppressive reagent taurolidine is an inhibitor of protein biosynthesis. Int J Cancer. 2004, 112: 225-230. 10.1002/ijc.20393.CrossRef
33.
go back to reference Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkötter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J of Investigative Surgery. 2007, 20: 339-348. 10.1080/08941930701772157.CrossRef Chromik AM, Daigeler A, Hilgert C, Bulut D, Geisler A, Liu V, Otte JM, Uhl W, Mittelkötter U: Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J of Investigative Surgery. 2007, 20: 339-348. 10.1080/08941930701772157.CrossRef
34.
go back to reference Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 2008, 27: 82-10.1186/1756-9966-27-82.CrossRef Daigeler A, Brenzel C, Bulut D, Geisler A, Hilgert C, Lehnhardt M, Steinau HU, Flier A, Steinstraesser L, Klein-Hitpass L, et al: TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma. J Exp Clin Cancer Res. 2008, 27: 82-10.1186/1756-9966-27-82.CrossRef
35.
go back to reference Abramjuk C, Bueschges M, Schnorr J, Jung K, Staack A, Lein M: Divergent effects of taurolidine as potential anti-neoplastic agent: Inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep. 2009, 22: 409-414. Abramjuk C, Bueschges M, Schnorr J, Jung K, Staack A, Lein M: Divergent effects of taurolidine as potential anti-neoplastic agent: Inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep. 2009, 22: 409-414.
36.
go back to reference Rodak R, Kubota H, Ishihara H, Eugster H-P, Könü D, Möhler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005, 102: 1055-1068. 10.3171/jns.2005.102.6.1055.CrossRef Rodak R, Kubota H, Ishihara H, Eugster H-P, Könü D, Möhler H, Yonekawa Y, Frei K: Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg. 2005, 102: 1055-1068. 10.3171/jns.2005.102.6.1055.CrossRef
37.
go back to reference Wang J, Yi J: Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008, 7: 1875-1884.CrossRef Wang J, Yi J: Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008, 7: 1875-1884.CrossRef
38.
go back to reference Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004, 3: 294-300. 10.1177/1534735404270335.CrossRef Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther. 2004, 3: 294-300. 10.1177/1534735404270335.CrossRef
39.
go back to reference Engel RH, Evens AM: Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci. 2006, 11: 300-312. 10.2741/1798.CrossRef Engel RH, Evens AM: Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci. 2006, 11: 300-312. 10.2741/1798.CrossRef
40.
go back to reference Ozben T: Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007, 96: 2181-2196. 10.1002/jps.20874.CrossRef Ozben T: Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007, 96: 2181-2196. 10.1002/jps.20874.CrossRef
41.
go back to reference Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008, 29: 1742-1750. 10.1093/carcin/bgn167.CrossRef Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, Ngan HY: Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis. 2008, 29: 1742-1750. 10.1093/carcin/bgn167.CrossRef
42.
go back to reference Constantinou C, Papas KA, Constantinou AI: Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy?. Curr Cancer Drug Targets. 2009, 9: 717-728. 10.2174/156800909789271512.CrossRef Constantinou C, Papas KA, Constantinou AI: Caspase-independent pathways of programmed cell death: the unraveling of new targets of cancer therapy?. Curr Cancer Drug Targets. 2009, 9: 717-728. 10.2174/156800909789271512.CrossRef
43.
go back to reference de Bruin EC, Medema JP: Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev. 2008, 34: 737-749. 10.1016/j.ctrv.2008.07.001.CrossRef de Bruin EC, Medema JP: Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev. 2008, 34: 737-749. 10.1016/j.ctrv.2008.07.001.CrossRef
Metadata
Title
Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines
Authors
Ansgar M Chromik
Adrien Daigeler
Daniel Bulut
Annegret Flier
Christina May
Kamran Harati
Jan Roschinsky
Dominique Sülberg
Peter R Ritter
Ulrich Mittelkötter
Stephan A Hahn
Waldemar Uhl
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-21

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine